- Home
- Europe Natural Killer Nk Cell Therapeutics Market
Europe Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
- Published Date: September, 2022 | Report ID: CLS-502 | No of pages: 200 | Format:
Europe natural killer (NK) cell therapeutics market is projected to register a CAGR of 41.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation:
Europe Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, rest of Europe) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Europe natural killer (NK) cell therapeutics market are:
Increase in patient population with chronic diseases
Increasing investment in research and development
Market Players:
The key market players for Europe natural killer (NK) cell therapeutics market are listed below:
Merck KGaA
Bristol-Myers Squibb Company
Glycostem
Kiadis Pharma
Cytovia Therapeutics
Nkarta, Inc.
Nektar
ImmunityBio, Inc.
Brink Biologics, Inc.
Biohaven Pharmaceuticals
Fate Therapeutics
EMERcell
Phio Pharmaceuticals
PersonGen BioTherapeutics
Innate Pharma, Inc.
INmuneBIO
Gamida Cell
Acepodia Inc.
Affimed GmbH
Multimmune GmbH
iCell Gene Therapeutics
Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals Inc.
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 30 1.1 OBJECTIVES OF THE STUDY 30 1.2 MARKET DEFINITION 30 1.3 OVERVIEW OF EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET 30 1.4 LIMITATIONS 32 1.5 MARKETS COVERED 33 2 MARKET SEGMENTATION 35 2.1 MARKETS COVERED 35 2.2 GEOGRAPHICAL SCOPE 36 2.3 YEARS CONSIDERED FOR THE STUDY 37 2.4 CURRENCY AND PRICING 37 2.5 DBMR TRIPOD DATA VALIDATION MODEL 38 2.6 MULTIVARIATE MODELLING 41 2.7 THERAPEUTICS LIFELINE CURVE 41 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42 2.9 DBMR MARKET POSITION GRID 43 2.10 SECONDARY SOURCES 45 2.11 ASSUMPTIONS 45 3 EXECUTIVE SUMMARY 46 3.1 EPIDEMIOLOGY 51 3.2 PESTEL ANALYSIS 52 3.3 PORTERS FIVE FORCES MODEL 53 3.4 INDUSTRIAL INSIGHTS: 54 3.5 PIPELINE ANALYSIS 56 4 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: REGULATIONS 57 5 MARKET OVERVIEW 59 5.1 DRIVERS 61 5.1.1 INCREASE IN USAGE OF NATURAL KILLER (NK) CELLS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES 61 5.1.2 INCREASE IN PATIENT POPULATION WITH CHRONIC DISEASES 61 5.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES 62 5.1.4 ADOPTION OF NATURAL KILLER (NK) CELL THERAPY IN EMERGING MARKETS 62 5.2 RESTRAINTS 63 5.2.1 LACK OF SPECIFICITY AND POOR IN-VIVO SURVIVAL OF THE CELLS 63 5.2.2 ADVERSE SIDE EFFECTS OF THERAPIES 63 5.2.3 HIGH COST ASSOCIATED WITH THE THERAPIES 64 5.3 OPPORTUNITIES 65 5.3.1 ADVANCEMENT IN NATURAL KILLER (NK) CELL THERAPIES 65 5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 65 5.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR 66 5.4 CHALLENGES 66 5.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES 66 5.4.2 LACK OF SPECIFIC TREATMENT BY NATURAL KILLER (NK) CELLS 67 5.4.3 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 67 6 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS 69 6.1 OVERVIEW 70 6.2 NK CELL THERAPIES 73 6.3 NK CELL DIRECTED ANTIBODIES 73 7 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES 75 7.1 OVERVIEW 76 7.2 ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) 79 7.3 BISPECIFIC ANTIBODIES 80 8 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION 81 8.1 OVERVIEW 82 8.2 CANCER 85 8.2.1 SOLID TUMORS 86 8.2.2 HEMATOLOGIC MALIGNANCIES 86 8.2.2.1 MULTIPLE MYELOMA 87 8.2.2.2 ACUTE MYELOID LEUKEMIA (AML) 87 8.2.2.3 LYMPHOMA 87 8.2.2.4 OTHERS 87 8.2.3 OTHERS 87 8.3 IMMUNOPROLIFERATIVE DISORDERS 87 8.4 ACUTE INFECTIOUS DISEASES 88 8.5 GASTROINTESTINAL DISEASES 88 8.6 OTHERS 89 9 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 91 9.1 OVERVIEW 92 9.2 HOSPITALS 95 9.3 SPECIALTY CLINICS 95 9.4 RESEARCH & ACADEMIC INSTITUTES 96 10 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 98 10.1 OVERVIEW 99 10.2 HOSPITAL PHARMACIES 102 10.3 DIRECT TENDER 102 10.4 OTHERS 103 11 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION 104 11.1 EUROPE 105 11.1.1 GERMANY 112 11.1.2 FRANCE 114 11.1.3 ITALY 116 11.1.4 U.K. 118 11.1.5 SPAIN 120 11.1.6 NETHERLANDS 122 11.1.7 RUSSIA 124 11.1.8 SWITZERLAND 126 11.1.9 TURKEY 128 11.1.10 AUSTRIA 130 11.1.11 NORWAY 132 11.1.12 HUNGARY 134 11.1.13 LITHUANIA 136 11.1.14 IRELAND 138 11.1.15 POLAND 140 11.1.16 LUXEMBOURG 142 11.1.17 REST OF EUROPE 144 12 EUROPE NATURAL KILLER (NK) CELLS THERAPEUTICS MARKET, COMPANY LANDSCAPE 145 12.1 COMPANY SHARE ANALYSIS: EUROPE 145 13 SWOT ANALYSIS 146 14 COMPANY PROFILE 147 14.1 MERCK KGAA 147 14.1.1 COMPANY SNAPSHOT 147 14.1.2 RECENT FINANCIALS 147 14.1.3 PRODUCT PORTFOLIO 148 14.1.4 RECENT DEVELOPMENTS 148 14.2 BRISTOL-MYERS SQUIBB COMPANY 150 14.2.1 COMPANY SNAPSHOT 150 14.2.2 RECENT FINANCIALS 150 14.2.3 PRODUCT PORTFOLIO 151 14.2.4 RECENT DEVELOPMENTS 151 14.3 GLYCOSTEM 153 14.3.1 COMPANY SNAPSHOT 153 14.3.2 PRODUCT PORTFOLIO 153 14.3.3 RECENT DEVELOPMENTS 153 14.4 INNATE PHARMA, INC. 155 14.4.1 COMPANY SNAPSHOT 155 14.4.2 REVENUE ANALYSIS 155 14.4.3 PRODUCT PORTFOLIO 156 14.4.4 RECENT DEVELOPMENTS 156 14.5 REGENERON PHARMACEUTICALS INC. 158 14.5.1 COMPANY SNAPSHOT 158 14.5.2 RECENT FINANCIALS 158 14.5.3 PRODUCT PORTFOLIO 159 14.5.4 RECENT DEVELOPMENTS 159 14.6 TAKEDA PHARMACEUTICAL COMPANY LIMITED 160 14.6.1 COMPANY SNAPSHOT 160 14.6.2 RECENT FINANCIALS 160 14.6.3 PRODUCT PORTFOLIO 161 14.6.4 RECENT DEVELOPMENTS 161 14.7 INMUNEBIO 162 14.7.1 COMPANY SNAPSHOT 162 14.7.2 REVENUE ANALYSIS 162 14.7.3 PRODUCT PORTFOLIO 163 14.7.4 RECENT DEVELOPMENTS 163 14.8 KIADIS PHARMA 165 14.8.1 COMPANY SNAPSHOT 165 14.8.2 REVENUE ANALYSIS 165 14.8.3 PRODUCT PORTFOLIO 166 14.8.4 RECENT DEVELOPMENTS 166 14.9 ACEPODIA INC. 168 14.9.1 COMPANY SNAPSHOT 168 14.9.2 PRODUCT PORTFOLIO 168 14.9.3 RECENT DEVELOPMENTS 168 14.10 AFFIMED GMBH 170 14.10.1 COMPANY SNAPSHOT 170 14.10.2 RECENT FINANCIALS 170 14.10.3 PRODUCT PORTFOLIO 171 14.10.4 RECENT DEVELOPMENTS 171 14.11 BIOHAVEN PHARMACEUTICALS 173 14.11.1 COMPANY SNAPSHOT 173 14.11.2 REVENUE ANALYSIS 173 14.11.3 PRODUCT PORTFOLIO 174 14.11.4 RECENT DEVELOPMENTS 174 14.12 BRINK BIOLOGICS, INC. 175 14.12.1 COMPANY SNAPSHOT 175 14.12.2 PRODUCT PORTFOLIO 175 14.12.3 RECENT DEVELOPMENT 175 14.13 CYTOVIA THERAPEUTICS 176 14.13.1 COMPANY SNAPSHOT 176 14.13.2 PRODUCT PORTFOLIO 176 14.13.3 RECENT DEVELOPMENTS 176 14.14 EMERCELL 178 14.14.1 COMPANY SNAPSHOT 178 14.14.2 PRODUCT PORTFOLIO 178 14.14.3 RECENT DEVELOPMENTS 178 14.15 FATE THERAPEUTICS 179 14.15.1 COMPANY SNAPSHOT 179 14.15.2 REVENUE ANALYSIS 179 14.15.3 PRODUCT PORTFOLIO 180 14.15.4 RECENT DEVELOPMENTS 180 14.16 GAMIDA CELL 182 14.16.1 COMPANY SNAPSHOT 182 14.16.2 PRODUCT PORTFOLIO 182 14.16.3 RECENT DEVELOPMENTS 183 14.17 ICELL GENE THERAPEUTICS 184 14.17.1 COMPANY SNAPSHOT 184 14.17.2 PRODUCT PORTFOLIO 184 14.17.3 RECENT DEVELOPMENT 184 14.18 IMMUNITYBIO, INC. 185 14.18.1 COMPANY SNAPSHOT 185 14.18.2 REVENUE ANALYSIS 185 14.18.3 PRODUCT PORTFOLIO 186 14.18.4 RECENT DEVELOPMENTS 186 14.19 MULTIMMUNE GMBH 187 14.19.1 COMPANY SNAPSHOT 187 14.19.2 PRODUCT PORTFOLIO 187 14.19.3 RECENT DEVELOPMENTS 187 14.20 NEKTAR 188 14.20.1 COMPANY SNAPSHOT 188 14.20.2 REVENUE ANALYSIS 188 14.20.3 PRODUCT PORTFOLIO 189 14.20.4 RECENT DEVELOPMENTS 189 14.21 NKARTA, INC. 190 14.21.1 COMPANY SNAPSHOT 190 14.21.2 PRODUCT PORTFOLIO 190 14.21.3 RECENT DEVELOPMENTS 190 14.22 PERSONGEN BIOTHERAPEUTICS 192 14.22.1 COMPANY SNAPSHOT 192 14.22.2 PRODUCT PORTFOLIO 192 14.22.3 RECENT DEVELOPMENTS 192 14.23 PHIO PHARMACEUTICALS 194 14.23.1 COMPANY SNAPSHOT 194 14.23.2 PRODUCT PORTFOLIO 194 14.23.3 RECENT DEVELOPMENTS 194 15 QUESTIONNAIRE 196 16 RELATED REPORTS 200Segmentation
Short Description Europe Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, rest of Europe) Industry Trends and Forecast to 2029 Market Definition: Natural killer (NK) cells are the large granular lymphocytes which have the ability to quickly respond to a pathological challenge. Natural killer cells are the important component of innate immune system and play an important role in generating immune response against the malignancies and infectious diseases caused by viral pathogens. Natural killer (NK) cells have been recognized to induce direct killing of targeted cells involving cancer cells. These have the ability to recognize the multitude of infected cells without being dependent on a single antigen expressing cells. NK cells secrete cytokines and chemokines which recruit other immune cells such as T cells and B cells which enhances the immune response against the tumor cells. As Natural killer (NK) cells do not express T cell receptors, they induce low risk of graft-versus-host disease. The effectiveness of NK cells therapies can be also be enhanced by genetically modified the NK cells so as to obtain highly specific and persistent cell lines. NK cell therapies can also be used with mono-clonal antibodies and T-cell therapies which again enhances its anti-tumor activity. Increase in usage of natural killer cells for the treatment of cancer and infectious disease is a key factor responsible for market growth. Along with this rise in patients population with chronic disease and rise in the awareness about immunotherapies boosting the market growth. Market Segmentation: Natural killer (NK) cell therapeutics market is categorized into four notable segments which are based on therapeutics, approaches, application, end user, and distribution channel. On the basis of therapeutics, the natural killer (NK) cell therapeutics market is segmented into NK cell therapies and NK cell directed antibodies On the basis of approaches, the natural killer (NK) cell therapeutics market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies. On the basis of application, the natural killer (NK) cell therapeutics market is segmented into cancer, acute infectious diseases, gastrointestinal diseases and others. Cancer is further sub-segmented into solid tumors, hematologic malignancies and others. Hematologic malignancies are further sub-segmented into multiple myeloma, acute myeloid leukemia (AML), lymphoma and others. On the basis of end user, the natural killer (NK) cell therapeutics market is segmented into hospitals, specialty clinics, and research & academic institutes On the basis of distribution channel, the natural killer (NK) cell therapeutics market is segmented into hospital pharmacies, direct tender, others. Market Players The key market players for natural killer (NK) cell therapeutics market are listed below: Merck KGaA Bristol-Myers Squibb Company Glycostem Kiadis Pharma Cytovia Therapeutics Nkarta, Inc. Nektar ImmunityBio, Inc. Brink Biologics, Inc. Biohaven Pharmaceuticals Fate Therapeutics EMERcell Phio Pharmaceuticals PersonGen BioTherapeutics Innate Pharma, Inc. INmuneBIO Gamida Cell Acepodia Inc. Affimed GmbH Multimmune GmbH iCell Gene Therapeutics Takeda Pharmaceutical Company Limited Regeneron Pharmaceuticals Inc.Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.